The observation of enriched Th17 cells within active MS brain lesions crossing the BBB, alongside the positive correlation between IL-17A production by myelin basic protein-primed CD4+ T cells from peripheral blood mononuclear cells (PBMCs) and disease activity, has implicated type 17 immunity in the pathogenesis of MS [174–176]. This evidence concerns the gene MBP and myeloid sarcoma.